Overview

Dose Finding Study of CHF 4226 for Treating Patients With COPD

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the optimal once-daily dose of CHF 4226 to be further developed for the treatment of patients with COPD.
Phase:
Phase 2
Details
Lead Sponsor:
Chiesi Farmaceutici S.p.A.
Collaborator:
Chiesi Pharmaceuticals Inc.
Treatments:
Salmeterol Xinafoate